3,774 Shares in Hologic, Inc. $HOLX Purchased by Fox Run Management L.L.C.

Fox Run Management L.L.C. acquired a new stake in Hologic, Inc. (NASDAQ:HOLX) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 3,774 shares of the medical equipment provider’s stock, valued at approximately $246,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Allworth Financial LP increased its holdings in Hologic by 46.0% in the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock worth $40,000 after acquiring an additional 216 shares in the last quarter. Edgestream Partners L.P. acquired a new stake in shares of Hologic in the first quarter valued at about $1,038,000. Massachusetts Financial Services Co. MA increased its stake in shares of Hologic by 11.1% during the first quarter. Massachusetts Financial Services Co. MA now owns 49,209 shares of the medical equipment provider’s stock worth $3,040,000 after purchasing an additional 4,918 shares in the last quarter. Wealthfront Advisers LLC raised its position in shares of Hologic by 300.7% during the 1st quarter. Wealthfront Advisers LLC now owns 45,083 shares of the medical equipment provider’s stock worth $2,785,000 after purchasing an additional 33,833 shares during the last quarter. Finally, Larson Financial Group LLC lifted its stake in Hologic by 6,016.7% in the 1st quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 722 shares in the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of the business’s stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the sale, the chief executive officer directly owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. The trade was a 10.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Christiana Stamoulis sold 7,402 shares of the company’s stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $73.07, for a total value of $540,864.14. Following the completion of the sale, the director owned 47,336 shares in the company, valued at approximately $3,458,841.52. This represents a 13.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 1.88% of the stock is currently owned by corporate insiders.

Hologic Price Performance

Hologic stock opened at $74.26 on Friday. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $80.31. The firm has a market cap of $16.52 billion, a PE ratio of 30.81, a price-to-earnings-growth ratio of 2.54 and a beta of 0.65. The company’s 50 day moving average is $69.62 and its two-hundred day moving average is $65.57.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.03 billion. During the same period last year, the business earned $1.01 EPS. The company’s revenue was up 6.2% on a year-over-year basis. On average, research analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on HOLX shares. Wall Street Zen cut Hologic from a “buy” rating to a “hold” rating in a research report on Wednesday, October 1st. Royal Bank Of Canada upgraded shares of Hologic from a “sector perform” rating to an “outperform” rating and increased their target price for the company from $72.00 to $87.00 in a research report on Wednesday, August 6th. Raymond James Financial downgraded shares of Hologic from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, October 22nd. Mizuho lowered shares of Hologic from an “outperform” rating to a “neutral” rating and boosted their price target for the stock from $70.00 to $78.00 in a research report on Thursday, October 23rd. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hologic in a research note on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and thirteen have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $79.77.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.